Brazil regulatory agency approves tafasitamab combo in R/R follicular lymphoma
Beyond this new indication, the drug is already approved in Brazil and the European Union for relapsed or refractory diffuse large B-cell lymphoma,
Lymphoma
Indolent B-Cell Lymphomas
News
Leukemia
Acute Myeloid Leukemia
Tandem Meetings 2026
Quizartinib similar to placebo in impact on AML patient-reported outcomes, QoL
Analysis of the QuANTUM-First phase 3 trial found that the impact of quizartinib on patient-reported outcomes and health-related quality of life (QoL) were
Cellular Therapy
Lymphoma
Indolent B-Cell Lymphomas
News
FDA approves subcutaneous mosunetuzumab in relapsed or refractory follicular lymphoma
The US Food and Drug Administration (FDA) approved mosunetuzumab (Lunsumio VELO), a CD20xCD3 bispecific antibody, as a subcutaneous formulation for adult patients with
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
SOHO UK
News
SOHO Insider Podcast
Dr. Iacoboni on improving CAR T-cell therapy outcomes in lymphoma
Gloria Iacoboni, MD, PhD, a hematologist at Vall d’Hebron University Hospital in Barcelona, Spain, spoke with Dr. James Day, a clinical research training
Leukemia
Acute Lymphoblastic Leukemia
Lymphoma
Aggressive B-Cell Lymphomas
Multiple Myeloma
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
News
Drs. Krish Patel and Gwen Nichols join SOHO Insider community oncology series
SOHO Insider is pleased to announce two new upcoming sessions in our Community Oncology Brown Bag Series, hosted by Loretta J. Nastoupil, MD.
Leukemia
Acute Lymphoblastic Leukemia
ASH 2025
News
Video Interviews
Drs. Zheng and Bona discuss financial toxicity in pediatric ALL
Daniel Zheng, MD, a pediatric oncologist at the Children's Hospital of Philadelphia, and Chiara Bona, MD, a pediatric oncologist at Dana-Farber Boston Children's
Leukemia
Acute Lymphoblastic Leukemia
SOHO UK
Multiple Myeloma
Myelodysplastic Syndromes
News
Video Interviews
Dr. Jessica Manson discusses multidisciplinary HLH management at SOHO UK
Dr. Manson covers the importance of treating the underlying driver of HLH to prevent recurrence and improve patient outcomes. She also highlights resources
Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Indolent B-Cell Lymphomas
News
China NMPA approves pirtobrutinib in relapsed/refractory CLL/SLL
The approval is based on the phase 3 BRUIN CLL-321 trial, the first randomized study in patients pre-treated with a covalent BTK inhibitor.
Cellular Therapy
Multiple Myeloma
News
FDA accepts NDA for iberdomide in relapsed/refractory myeloma
Iberdomide is the first in a new class of medicines called cereblon E3 ligase modulator (CELMoD) agents, which utilize targeted protein degradation to
Lymphoma
Aggressive B-Cell Lymphomas
News
FDA accepts NDA for tirabrutinib in relapsed or refractory PCNSL
The filing was supported by results from the phase 2 PROSPECT study, which demonstrated an overall response rate of 67 percent and a